Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
- PMID: 7664822
- DOI: 10.1016/0922-4106(95)90013-6
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
Abstract
Pramipexole (SND 919; 2-amino-4,5,6,7-tetrahydro-6-propylamino-benzthiazole-dihydrochlor ide) is a potent dopamine autoreceptor agonist. We have carried out an analysis of the binding affinities of dopamine D2L, D2S, D3, and D4 receptors for pramipexole using both [3H]pramipexole and [3H]spiperone as radioligands at cloned and heterologously expressed receptors. Studies were carried out using rat and human D2L, D2S and D3 receptors with equivalent results. When the binding of pramipexole to the high affinity, guanine nucleotide-sensitive state of each receptor was analyzed, pramipexole is most selective for D3 compared to D2 and D4 receptors. These results indicate a 5-fold selectivity of pramipexole for D3 receptors, while quinpirole and bromocriptine are non-selective or more D2/D4 receptor selective. Two measurements of receptor activation for dopamine D2, D3, and D4 receptors also show that pramipexole is most potent for activation of D3 receptors. The dopamine D3 receptor selectivity of pramipexole may explain the previously described properties of this drug, including its potent autoreceptor preference.
Similar articles
-
Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.Eur J Pharmacol. 1995 Apr 24;277(2-3):209-14. doi: 10.1016/0014-2999(95)00069-w. Eur J Pharmacol. 1995. PMID: 7493610
-
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.Synapse. 2005 Nov;58(2):122-8. doi: 10.1002/syn.20193. Synapse. 2005. PMID: 16088951
-
Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.Eur J Pharmacol. 1996 Sep 19;312(1):35-44. doi: 10.1016/0014-2999(96)00454-2. Eur J Pharmacol. 1996. PMID: 8891576
-
Pre-clinical studies of pramipexole: clinical relevance.Eur J Neurol. 2000 May;7 Suppl 1:15-20. doi: 10.1046/j.1468-1331.2000.0070s1015.x. Eur J Neurol. 2000. PMID: 11054154 Review.
-
Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. Clin Neuropharmacol. 1998. PMID: 9617505 Review.
Cited by
-
A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17113-8. doi: 10.1073/pnas.012260599. Epub 2002 Dec 13. Proc Natl Acad Sci U S A. 2002. PMID: 12482941 Free PMC article.
-
Pramipexole extended release: a novel treatment option in Parkinson's disease.Parkinsons Dis. 2010 Dec 19;2010:612619. doi: 10.4061/2010/612619. Parkinsons Dis. 2010. PMID: 21209705 Free PMC article.
-
The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture.Neurosci Lett. 2023 Sep 25;814:137419. doi: 10.1016/j.neulet.2023.137419. Epub 2023 Aug 7. Neurosci Lett. 2023. PMID: 37558176 Free PMC article.
-
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445. Br J Pharmacol. 2013. PMID: 24517644 Free PMC article.
-
Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.Neuropharmacology. 2017 Mar 1;114:77-87. doi: 10.1016/j.neuropharm.2016.11.014. Epub 2016 Nov 23. Neuropharmacology. 2017. PMID: 27889491 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases